LAVA Therapeutics

$4.99 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest


About LAVA Therapeutics

LAVA Therapeutics N.V. operates as a biotechnology company. The Company develops proprietary T-cell engaging bispecific antibodies to treat cancer, as well as immune oncology biopharmaceuticals delivering the primary targeted treatment in combination with immune recruiting and activating functionality. LAVA Therapeutics serves customers worldwide.

Stock Analysis

last close $4.99
1-mo return -2.2%
3-mo return -34.6%
avg daily vol. 35.95T
52-week high 17.2
52-week low 4.22
market cap. $129M
forward pe -
annual div. -
roe -232.2%
ltg forecast -
dividend yield -
annual rev. $4M
inst own. 60.4%

Subscribe now for daily local and international financial news